Seres Therapeutics, Inc. (MCRB) Receives Average Rating of “Buy” from Brokerages
Seres Therapeutics, Inc. (NASDAQ:MCRB) has been assigned an average recommendation of “Buy” from the twelve brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $19.14.
A number of brokerages have recently commented on MCRB. BidaskClub cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Canaccord Genuity set a $20.00 target price on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. Cowen Inc reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC purchased a new position in Seres Therapeutics during the 3rd quarter valued at $170,000. Perceptive Advisors LLC purchased a new position in Seres Therapeutics during the 3rd quarter valued at $2,165,000. Schwab Charles Investment Management Inc. boosted its holdings in Seres Therapeutics by 12.8% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 103,286 shares of the biotechnology company’s stock valued at $1,657,000 after acquiring an additional 11,743 shares during the period. Schroder Investment Management Group purchased a new position in Seres Therapeutics during the 3rd quarter valued at $1,088,000. Finally, JPMorgan Chase & Co. boosted its holdings in Seres Therapeutics by 39.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after acquiring an additional 106,479 shares during the period. Institutional investors own 77.04% of the company’s stock.
Shares of Seres Therapeutics (NASDAQ MCRB) opened at $9.54 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.22. The firm had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The company’s quarterly revenue was up 76.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.46) EPS. sell-side analysts predict that Seres Therapeutics will post -2.34 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Seres Therapeutics, Inc. (MCRB) Receives Average Rating of “Buy” from Brokerages” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/seres-therapeutics-inc-mcrb-receives-average-rating-of-buy-from-brokerages/1726591.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.